All In Biotech

Drug Trial Radar · NCT05758922

Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease

Randomized, Double Blind, Placebo Controlled, Multicenter, 12 Weeks Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease

Last checked: Nov 20, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

13

Actual

Start

Apr 24, 2023

Primary completion

Apr 19, 2024

Study completion May 5, 2026

Sponsor

Lead sponsor
Azafaros B.V.Industry
Sponsor type
Industry
First posted
Mar 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase 2 is a randomized, double-blind, placebo controlled, 12 weeks study with daily oral administration of AZ-3102 aiming to evaluate the safety and pharmacokinetic (PK) profile in GM2 Gangliosidosis and Niemann-Pick type C disease (NP-C) patients. After approval by the country health authorities, a double-blind extension period was proposed to the patients who complete the 12-week study.

Conditions

  • GM2 Gangliosidosis
  • Niemann-Pick Disease, Type C

Interventions

  • AZ-3102 (Dose 1)Drug

    Pharmaceutical form: capsule Route of administration: oral

  • PlaceboDrug

    Pharmaceutical form: capsule Route of administration: oral

  • AZ-3102 (Dose 2)Drug

    Pharmaceutical form: capsule Route of administration: oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety/tolerability: Incidence and severity of treatment emergent adverse eventsTime frame: Through study completion, up to Week 12
  2. Assessment of pharmacokinetic (PK) parameters in plasma: CmaxTime frame: Through study completion, up to Week 12
  3. Assessment of PK parameters in plasma: TmaxTime frame: Through study completion, up to Week 12
  4. Assessment of PK parameters in plasma: AUC0-24hTime frame: Concentration versus time curve calculated from time 0 to 24 hours (AUC0-24h)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital Pequeno Principe

    Curitiba, Brazil

  • Hospital de Clinicas de Porto Alegre

    Porto Alegre, Brazil

  • Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira

    Rio de Janeiro, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.